Literature DB >> 18983301

Direct antiglobulin test reactive with complement only in warm type autoimmune hemolytic anemia.

L Shvidel1, M Shtalrid, A Duek, M Haran, A Berrebi, E Sigler.   

Abstract

Direct antiglobulin test (DAT) with only complement detected on red blood cells is a rare laboratory finding, and its significance in the setting of warm autoimmune hemolytic anemia (AIHA) is controversial. During 2 years (2003-2004) 277 patients with positive DAT were recorded in the blood bank registries, 17 of them had DAT reactive with C3 alone with no cold agglutinin or other nonimmune causes for hemolysis diagnosed. Red cell eluate disclosed small amounts of IgG in two patients. In nine patients no signs of clinical hemolysis were found, however, all these patients had underlying conditions that are known to be associated with red cells autoantibodies (autoimmune disorder or malignancy). Eight patients developed AIHA, seven of them with severe hemolysis. Three patients had idiopathic AIHA, and the others have been diagnosed with infectious, lymphoproliferative and autoimmune disorders. In two patients with acute infection the hemolytic process spontaneously resolved, three responded to corticosteroid therapy, while three patients were refractory to two lines of drug therapy and underwent splenectomy. Reticulocytopenia was found in four patients. Our results emphasize that AIHA with DAT reactive with complement alone is a rare disorder and might be accompanied by severe, refractory to conventional treatment and life-threatening hemolysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18983301     DOI: 10.1111/j.1751-553X.2007.00985.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  1 in total

1.  Warm Autoimmune Hemolytic Anemia with a Direct Antiglobulin Test Positive for C3 and Negative for IgG: A Case Study and Analytical Literature Review of Incidence and Severity.

Authors:  Amruth R Palla; Farhad Khimani; Michael D Craig
Journal:  Clin Med Insights Case Rep       Date:  2013-04-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.